Antibody therapeutics companies develop engineered antibodies that target specific molecules involved in disease. These medicines are used across oncology, autoimmune disease, inflammatory conditions, infectious disease and other areas of clinical development.
This category includes companies working on:
Browse 75 UK antibody therapeutics companies below.
Global biopharma with UK manufacturing, commercial and clinical operations
MSD is a global biopharmaceutical company discovering, developing, manufacturing and marketing medicines and vaccines across oncology, infectious disease, immunology, cardiometabolic disease and animal health. Its UK operations span pharmaceutical manufacturing at Cramlington, Northumberland, which supplies medicines…
Global pharma company in immunology, vaccines, and oncology
GSK is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of medicines and vaccines. Its pipeline and portfolio span respiratory and immunology, oncology, HIV (through its specialist subsidiary ViiV Healthcare), and infectious diseases including vaccines.…
Fibroblast immunology platform targeting cancer and inflammatory disease
Mestag Therapeutics is a clinical-stage biotechnology company developing first-in-class antibody therapies that target activated fibroblasts to modulate immune responses in cancer and inflammatory disease. Its lead programme, MST-0312, is a FAP-targeted LTBR agonist bispecific antibody designed to induce tertiary…
Target discovery platform and antibody-based therapies for oncology
Oxford BioTherapeutics is an Oxford-based clinical-stage oncology company discovering and developing first-in-class antibody-based cancer therapies. Its proprietary platform identifies novel membrane protein targets directly from patient tumour samples, enabling the development of ADCs, immuno-oncology antibodies,…
UK affiliate of global family-owned biopharmaceutical company
Boehringer Ingelheim is a global family-owned biopharmaceutical company founded in 1885. Its Bracknell headquarters houses functions spanning research and development, regulatory affairs, pharmacovigilance, medical affairs, and commercial operations across its human pharma and animal health divisions. It operates…
Antibody discovery platform identifying therapeutics from resilient individuals
Alchemab Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics for neurodegenerative diseases, oncology, and immunology. Its platform combines deep B cell sequencing and machine learning to identify naturally protective antibodies from individuals resilient to specific diseases.…
Engineered patient cells for sustained therapeutic antibody production
Semper-B Therapeutics is a biotechnology company developing a cell-engineering platform intended to enable patients’ own cells to produce therapeutic antibodies over prolonged periods. The approach aims to achieve durable, precise modulation of immune activity by using engineered cells as a continuing source of…
Clinical-stage antibody-drug conjugate developer for cancer
Iksuda Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates for difficult-to-treat cancers. Its platform combines stable bioconjugation chemistry with tumour-selective payload activation to improve therapeutic index. Clinical programmes include IKS014, a HER2-targeting ADC, and…
Antibody fragment drug conjugate platform for solid tumour oncology
Antikor Biopharma is a pre-clinical stage biotechnology company developing antibody fragment drug conjugates for the treatment of solid tumours. The company's proprietary platform uses smaller antibody fragments rather than whole antibodies to achieve improved tumour penetration and faster systemic clearance compared…
Antibody inhibitors of metzincin proteases for eye disease and cancer
Vasgen develops antibody therapeutics for eye disease and cancer, focusing on enzymes known as metzincin proteases. Its discovery platform uses monoclonal antibodies to inhibit these enzymes selectively, offering a different approach to targets that have proved challenging for conventional small-molecule medicines.…
Viral vector platform for solid tumour immunotherapy
Akamis Bio is a clinical-stage oncology company developing oncolytic adenoviral therapeutics for solid tumours. Its platform delivers immunotherapeutic payloads directly to tumour sites following intravenous dosing, enabling tumour-localised expression of proteins including CD40 agonist antibodies and cytokines. Lead…
Takeda's UK clinical development and drug discovery operations
Takeda UK encompasses the British operations of Takeda Pharmaceutical Company, one of the world's largest biopharmaceutical companies. The London-based Takeda Development Centre Europe leads clinical development, regulatory affairs, and medical affairs across oncology, neuroscience, gastrointestinal disease, rare…
Multivalent linker technologies for antibody-drug conjugate therapeutics
Spirea is a biopharmaceutical company developing antibody-drug conjugate technologies for targeted cancer treatment. Its multivalent linker platform is designed to attach a wider range of drug payloads to antibodies while enabling higher payload loading and controlled delivery. Spirea conducts preclinical research on…
Monoclonal antibodies for viral infectious disease
RQ Biotechnology is a passive immunisation company discovering and developing long-acting monoclonal antibodies to provide immediate protection against viral infections in immunocompromised and vulnerable populations. Founded by members of the UK COVID-19 Antibody Taskforce and co-founded with LifeArc, the company's…
Global biopharma with major UK R&D and regulatory operations
Pfizer Limited is the principal UK subsidiary of Pfizer Inc., one of the world's largest biopharmaceutical companies. Its Sandwich, Kent site houses pharmaceutical sciences, global clinical supplies, quality assurance, and worldwide safety and regulatory operations serving over 175 markets. A Devices Centre of…
KnotBody therapeutics for ion channel and GPCR diseases
Maxion Therapeutics is a biotechnology company developing a pipeline of KnotBody therapeutics for diseases driven by ion channel and G protein-coupled receptor dysfunction. The platform combines naturally occurring mini-proteins with antibodies to generate potent, selective and long-acting biologics against target…
CreaTap antibody engineering for improved solid tumour penetration
Creasallis is a biotechnology company developing antibody engineering technologies intended to improve drug delivery into solid tumours. Its patented CreaTap platform modifies therapeutic antibodies to promote deeper penetration into tumour tissue. The approach is under development for monoclonal antibodies,…
T cell-engaging multispecific antibody fragments for solid tumours
Crescendo Biologics is a clinical-stage biopharmaceutical company developing multispecific therapeutics based on fully human single-domain antibody fragments engineered for enhanced tumour penetration and selective T cell activation within the tumour microenvironment. Its lead programme is in Phase 1b clinical trials…
Ovine polyclonal therapeutics developer and antivenom manufacturer
MicroPharm is a specialty pharmaceutical company developing and manufacturing ovine polyclonal antibody therapeutics for the treatment of acute toxic and infectious conditions. The company's MHRA-licensed facilities in West Wales produce a portfolio of clinical-grade antivenoms, including products acquired from Sanofi…
Isoform-specific antibody therapeutics for vascular disease
IsomAb is a biotechnology company developing isoform-specific antibody therapeutics for serious vascular diseases. Its lead programme, ISM-001, targets VEGF-A165b, an anti-angiogenic splice isoform implicated in peripheral arterial disease and chronic limb-threatening ischaemia. The company uses a…